Green SR, Singh V, O’Byrne W. Hope for New Jersey’s city hospitals: the Camden Initiative. Perspect Health Inf Manag. 2010;7(Spring):1d.

PubMed  PubMed Central  Google Scholar 

Clark RE, Baxter JD, Aweh G, O’Connell E, Fisher WH, Barton BA. Risk factors for relapse and higher costs among Medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abuse Treat. 2015;57:75–80. https://doi.org/10.1016/j.jsat.2015.05.001.

Article  PubMed  PubMed Central  Google Scholar 

Hampton MD, Chafetz L, Portillo C. Differences in substance-related risk behavior between dual and triple diagnosed severely mentally ill adults. Ment Health Subst Use Dual Diagn. 2012;5(1):52–63. https://doi.org/10.1080/17523281.2011.608374.

Article  Google Scholar 

Wogen J, Restrepo MT. Human Rights, stigma, and substance use. Health Hum Rights. 2020;22(1):51–60.

PubMed  PubMed Central  Google Scholar 

Emeche U. Is a strategy focused on super-utilizers equal to the task of health care system transformation? Yes. Ann Fam Med. 2015;13(1):6–7. https://doi.org/10.1370/afm.1746.

Article  PubMed  PubMed Central  Google Scholar 

Pritchard D, Petrilla A, Hallinan S, Taylor DH, Schabert VF, Dubois RW. What contributes most to high health care costs? Health care spending in high resource patients. J Manag Care Spec Pharm. 2016;22(2):102–9. https://doi.org/10.18553/jmcp.2016.22.2.102.

Article  PubMed  PubMed Central  Google Scholar 

Roszak AR, Jensen FR, Wild RE, Yeskey K, Handrigan MT. Implications of the emergency medical treatment and labor act (EMTALA) during public health emergencies and on alternate sites of care. Disaster Med Public Health Prep. 2009;3(S2):S172-5. https://doi.org/10.1097/DMP.0b013e3181c6b664.

Article  PubMed  Google Scholar 

Logge WB, Lee K, Yen CF. Editorial: dual disorders in addiction and mood disorders: comorbidity or specific diagnosis? Front Psychiatry. 2024;15:1490922. https://doi.org/10.3389/fpsyt.2024.1490922.

Article  PubMed  PubMed Central  Google Scholar 

Milano G, Vergani HM, Cattedra S, et al. Co-occurring psychiatric and substance use disorders: clinical survey among a rural cohort of Italian patients. Neuropsychiatr Dis Treat. 2019;15:3453–9. https://doi.org/10.2147/NDT.S222567.

Article  PubMed  PubMed Central  Google Scholar 

John WS, Wu LT. Chronic non-cancer pain among adults with substance use disorders: prevalence, characteristics, and association with opioid overdose and healthcare utilization. Drug Alcohol Depend. 2020;209:107902. https://doi.org/10.1016/j.drugalcdep.2020.107902.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yazdanshenas H, Bazargan M, Smith J, Martins D, Motahari H, Orum G. Pain treatment among underserved older adult African Americans. J Am Geriatr Soc. 2016;64(10):2116–21. https://doi.org/10.1111/jgs.14302.

Article  PubMed  PubMed Central  Google Scholar 

Hämmig R, Kemter A, Strasser J, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99–105. https://doi.org/10.2147/SAR.S109919.

Article  PubMed  PubMed Central  Google Scholar 

Auriacombe M, Fatséas M, Dubernet J, Daulouède JP, Tignol J. French field experience with buprenorphine. Am J Addict. 2004;13(Suppl 1):S17–28. https://doi.org/10.1080/10550490490440780.

Article  PubMed  Google Scholar 

Button D, Hartley J, Robbins J, Levander XA, Smith NJ, Englander H. Low-dose buprenorphine initiation in hospitalized adults with opioid use disorder: a retrospective cohort analysis. J Addict Med. 2022;16(2):e105-11. https://doi.org/10.1097/ADM.0000000000000864.

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Academies of Sciences E, Division H, Policy M, on HS B, Disorder C on MAT for, Mancher OU, Leshner M. AI. The Effectiveness of Medication-Based Treatment for Opioid Use Disorder. In: Medications for Opioid Use Disorder Save Lives. National Academies Press (US); 2019. Accessed December 31, 2025. https://www.ncbi.nlm.nih.gov/books/NBK541393/

De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. Clin Drug Investig. 2021;41(5):425–36. https://doi.org/10.1007/s40261-021-01032-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kohan L, Potru S, Barreveld AM, et al. Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. Reg Anesth Pain Med. 2021;46(10):840–59. https://doi.org/10.1136/rapm-2021-103007.

Article  PubMed  Google Scholar 

Heslin KC, Singzon T, Aimiuwu O, Sheridan D, Hamilton A. From personal tragedy to personal challenge: responses to stigma among sober living home residents and operators. Sociol Health Illn. 2012;34(3):379–95. https://doi.org/10.1111/j.1467-9566.2011.01376.x.

Article  PubMed  Google Scholar 

Matthews S, Dwyer R, Snoek A. Stigma and Self-Stigma in Addiction. J Bioethic Inq. 2017;14(2):275–86. https://doi.org/10.1007/s11673-017-9784-y.

Article  Google Scholar 

Baptiste-Roberts K, Hossain M. Socioeconomic Disparities and Self-reported Substance Abuse-related Problems. Addict Health. 2018;10(2):112–22. https://doi.org/10.22122/ahj.v10i2.561.

Article  PubMed  PubMed Central  Google Scholar 

Raheemullah A, Benhamou OM, Kuo J, Lembke A. Buprenorphine Microdosing Cross Tapers: A Time for Change. Int J Environ Res Public Health. 2022;19(24):16436. https://doi.org/10.3390/ijerph192416436.

Article  PubMed  PubMed Central  Google Scholar 

Moe J, O’Sullivan F, Hohl CM, et al. Short communication: Systematic review on effectiveness of micro-induction approaches to buprenorphine initiation. Addict Behav. 2021;114:106740. https://doi.org/10.1016/j.addbeh.2020.106740.

Article  PubMed  Google Scholar 

Marwah R, Coons C, Myers J, Dumont Z. Buprenorphine-naloxon microdosing. Tool for opioid agonist therapy induction. Can Fam Physician. 2020;66(12):891–4. https://doi.org/10.46747/cfp.6612891.

Article  PubMed  PubMed Central  Google Scholar 

The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder. 2020 Focused Update. J Addict Med. 2020;14(2S Suppl 1):1–91. https://doi.org/10.1097/ADM.0000000000000633.

Article  Google Scholar 

Kumar R, Viswanath O, Saadabadi A. Buprenorphine. In: StatPearls. StatPearls Publishing; 2025. Accessed January 6, 2026. http://www.ncbi.nlm.nih.gov/books/NBK459126/

Adams KK, Waters K, Sobieraj DM. Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: an updated systematic review. Addict Sci Clin Pract. 2025;20(1):19. https://doi.org/10.1186/s13722-025-00548-z.

Article  PubMed  PubMed Central  Google Scholar 

Shulman M, Wai JM, Nunes EV. Buprenorphine treatment for opioid use disorder: an overview. CNS Drugs. 2019;33(6):567–80. https://doi.org/10.1007/s40263-019-00637-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reindel KL, DeAngelis MJ, Ferrara AS, et al. An Exploratory Study of Suboxone (Buprenorphine/Naloxone) Film Splitting: Cutting Methods, Content Uniformity, and Stability. Int J Pharm Compd. 2019;23(3):258–63.

PubMed  Google Scholar 

Togioka BM, Patel P. Buprenorphine and Naloxone. In: StatPearls. StatPearls Publishing; 2025. Accessed January 12, 2026. http://www.ncbi.nlm.nih.gov/books/NBK603725/

Ordean A, Tubman-Broeren M. Safety and efficacy of Buprenorphine-Naloxone in pregnancy: a systematic review of the literature. Pathophysiology. 2023;30(1):27–36. https://doi.org/10.3390/pathophysiology30010004.

Article  PubMed  PubMed Central  Google Scholar 

Coish R, Hardial J. Successful buprenorphine/naloxone low-dose induction in pregnancy: a case report. J Addict Med. 2023;17(1):114–6. https://doi.org/10.1097/ADM.0000000000001042.

Article  PubMed  Google Scholar 

Dermody ML, Lemon S, Kingdon L, Ruekert L. A retrospective study on the continuation of buprenorphine in the perioperative setting. Hosp Pharm. 2025;60(3):253–61. https://doi.org/10.1177/00185787241301348.

Article  CAS  PubMed